Clinical Trial Update: Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer [NA]

View source ↗

Summary

Clinical trial update indicating a study of dose-dense nab-paclitaxel (Abraxane) as adjuvant chemotherapy for breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)

Snippet

Sponsor: Harold J. Burstein, MD, PhD | Conditions: Breast Cancer | NA | Status: COMPLETED